Redhill Biopharma (RDHL) is developing RHB-104 to treat Crohn's disease by targeting its potential cause, the Mycobacterium avium subspecies paratuberculosis (MAP) bacterium. RDHL has an exclusive license for the only FDA-approved test to detect MAP in humans and is conducting a Phase III trial of RHB-104, a combination antibiotic therapy shown previously to be more effective than current treatments. The results of the Phase III trial in 2015 could validate RDHL's thesis that MAP causes Crohn's and demonstrate RHB-104 as a new treatment paradigm. At its current undervalued state with no analyst coverage, RDHL presents a promising investment opportunity.